Clinical trials: Alzheimer Dementia
Alzheimer Disease, Parkinson Disease
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
The role of disorders of socio-emotional processes in cerebral diseases such as Alzheimer's disease, frontal temporal dementia, Parkinson's disease, Huntington's disease, traumatic brain injury, stroke, focal lesions, has been…
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontal Dementia, Huntington Disease
- Trial name
- GREFEXII (NCT03052712)
- Testing
- social cognition
- Where
- France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Alzheimer's Disease
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
- Trial name
- NCT00203359
- Testing
- etanercept given by perispinal administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Tobinick, Edward Lewis, M.D.
Alzheimer Disease, Vascular Dementia
Working Memory Functioning in Alzheimer's Disease and Vascular Dementia
The aim of the present study is to investigate potential cognitive mechanisms contributing to working memory impairment in Alzheimer's disease and vascular dementia.
- Conditions
- Alzheimer Disease, Vascular Dementia, Mixed Dementias
- Trial name
- MEMTRAV-COG (NCT06321380)
- Testing
- Complex span task, Clinical neuropsychological assessment, Clinical neurospychological assessement
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Alzheimer's Disease
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
The study will evaluate the safety \& efficacy of AC-1204, a ketogenic compound, administered orally on a daily basis for 6 months.
- Trial name
- ALERT (NCT01211782)
- Testing
- caprylic triglyceride, long-chain triglyceride
- Where
- United States
- Sponsor
- Cerecin
Alzheimer Disease, Early Onset, Protein; Disease
Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography/mass…
- Trial name
- NCT04804618
- Where
- China
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Alzheimer Disease
A Study on the Effectiveness of Multidomain Intervention Program for Reducing Risks of Dementia
Investigators aimed to examine the feasibility and effectiveness of a multidomain intervention strategy involving intensive and maintenance programs aimed at reducing the risk of Alzheimer's disease (AD) in at-risk older adults.
- Trial name
- NCT03786510
- Testing
- Active control, Intensive + Maintenance program, Intensive program only
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Aging, Alzheimer Disease
Heart Rate and Breathing Effects on Attention and Memory
In the current study, we will examine how daily paced breathing affects plasma amyloid beta levels and the rate of learning in older adults.
- Conditions
- Aging, Alzheimer Disease, Age-related Cognitive Decline
- Trial name
- HeartBEAM (NCT05602220)
- Testing
- Brain training, Paced breathing
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
The objective of this study is to determine if comprehensive lifestyle changes may slow, stop, or reverse the progression of early-stage Alzheimer's disease.
- Trial name
- NCT04606420
- Testing
- Lifestyle medicine
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Preventive Medicine Research Institute
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
- Trial name
- MCI (NCT02016560)
- Testing
- florbetapir F 18, Flortaucipir F18, Brain PET Scan
- Where
- 27 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Alzheimer Disease
Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.
- Trial name
- BUENA (NCT03402503)
- Testing
- Montelukast buccal film
- Where
- 12 sites in Canada
- Volunteers
- 52 people
- Sponsor
- IntelGenx Corp.
Alzheimer Disease, Dementia
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
This study will evaluate Jigsawdio, a personalized multisensory jigsaw puzzle platform, for adults aged 60 years and older with mild cognitive impairment or mild dementia.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Trial name
- NCT07839286
- Testing
- Jigsawdio Multisensory Puzzle Platform, Standard Jigsaw Puzzle Activity
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Callahan-Young LLC DBA Jigsawdio
Dementia, Mild, Dementia of Alzheimer Type
Autonomic Involvement in Patient With Cognitive Decline
Prospective interventional study with a device for comparing autonomic parameters among patients with different forms of cognitive decline
- Trial name
- NCT06292741
- Testing
- Sudoscan
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Alzheimer's Disease
Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)
Alzheimer Disease (AD) is a progressive brain disease generally known as senile dementia. Our proposed study will establish safety and pharmacokinetics of Meganatural-AZ GSPE in AD subjects.
- Trial name
- NCT02033941
- Testing
- Meganatural-Az Grapeseed Extract
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hillel Grossman
Alzheimer's Disease
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
- Trial name
- NCT01097096
- Testing
- CAD106, Alum, MF59
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
The purpose of this study is to: Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after…
- Trial name
- NCT07214727
- Testing
- ALN-5288
- Where
- 13 sites in Canada, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer Disease
Study of ASN51 in Adults With Early Alzheimer's Disease
The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of…
- Trial name
- NCT06677203
- Testing
- ASN51
- Where
- 7 sites in United States
- Volunteers
- 123 people
- Sponsor
- Asceneuron S.A.
Alzheimer Disease, Early Onset, Parkinson Disease
Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal…
- Trial name
- NODAL (NCT06080659)
- Testing
- fMRI, CONFMEM
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
"Alzheimer's Disease" and "Lewy Body Disease"
Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.
Patients with memory disorders are experiencing different trends which are difficult to predict. Moreover, the distinction between Lewy body disease and Alzheimer's disease is not easy as both diseases can present similar…
- Trial name
- AlphaLewyMa (NCT01876459)
- Testing
- MRI, lumbar puncture, neuropsychological tests
- Where
- France
- Volunteers
- 265 people
- Sponsor
- University Hospital, Strasbourg, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.